Best BPC-157 Providers in 2026 — Ranked & Reviewed

BPC-157 is a synthetic peptide derived from a sequence found in human gastric juice, widely discussed for gut, tendon, and soft-tissue healing. It sits in a legally complicated spot — the FDA placed it on the do-not-compound list in 2023, so no compounding pharmacy can currently sell it lawfully, and most of what's sold online is an unregulated “research chemical” with no prescriber involved. See below for the current status.

New to BPC-157? Read our full BPC-157 guide — evidence, dosing, safety and side effects.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Why there’s no ranking here yet

On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding BPC-157 to the Section 503A Bulk Drug Substances List — a real, positive step. That vote is a recommendation only; the FDA and HHS still need to formally act on it before any compounding pharmacy can lawfully sell BPC-157 again. We audited our catalog and could not confirm a provider currently selling it in full compliance, so we're not ranking any until that changes.

We’d rather show nothing than list a provider who can’t legally sell this yet. We’re tracking the FDA’s decision and will rank compliant providers here the moment one exists.

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings